Market Cap | 30.11M | P/E | - | EPS this Y | 51.40% | Ern Qtrly Grth | - |
Income | -38.66M | Forward P/E | -1.89 | EPS next Y | 10.40% | 50D Avg Chg | -86.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -88.00% |
Dividend | N/A | Price/Book | 0.76 | EPS next 5Y | - | 52W High Chg | -95.00% |
Recommedations | 2.50 | Quick Ratio | 0.46 | Shares Outstanding | 10.77M | 52W Low Chg | - |
Insider Own | 26.08% | ROA | -96.80% | Shares Float | 8.43M | Beta | - |
Inst Own | 6.09% | ROE | -353.02% | Shares Shorted/Prior | 30.03K/43.04K | Price | 1.00 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 9,514 | Target Price | 10.00 |
Oper. Margin | - | Earnings Date | Nov 7 | Volume | 224,803 | Change | 0.00% |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
HC Wainwright & Co. | Buy | Aug 23, 24 |
HC Wainwright & Co. | Buy | Jun 6, 24 |
HC Wainwright & Co. | Buy | May 22, 24 |
HC Wainwright & Co. | Buy | May 1, 24 |
Oppenheimer | Perform | Apr 1, 24 |
HC Wainwright & Co. | Buy | Jan 17, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Chudnovsky Yekaterina | Director Director | Dec 22 | Buy | 5.81 | 1,213,000 | 7,047,530 | 1,915,639 | 12/26/23 |
Venkatesan Jay | See Remarks See Remarks | May 20 | Buy | 1.24 | 82,200 | 101,928 | 1,721,457 | 05/25/22 |
Nissenson Allen | Director Director | May 19 | Buy | 1.17 | 9,383 | 10,978 | 9,383 | 05/23/22 |
Venkatesan Jay | See Remarks See Remarks | Dec 16 | Buy | 2.55 | 41,625 | 106,144 | 1,358,486 | 12/20/21 |